Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Los Angeles, March 03, 2026 (GLOBE NEWSWIRE) -- Dave Announces Proposed Offering of Convertible Notes Company plans to enter into capped call transactions and repurchase shares of its common...
-
LITTLE ROCK, Ark., March 03, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its Chief Financial Officer and Treasurer, Paul Bullington, and Senior Vice...
-
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners...
-
PHOENIX, March 03, 2026 (GLOBE NEWSWIRE) -- Fold Holdings, Inc. (NASDAQ: FLD) (“Fold”), a bitcoin financial services company making it easy for individuals and businesses to earn, save, and spend...
-
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Chicago Atlantic BDC, Inc. (the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development...
-
Smithfield Foods to Announce Fourth Quarter and Full Year Fiscal 2025 Results on March 24, 2026
-
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized,...
-
WARRENVILLE, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water...
-
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized,...
-
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease...